Akebia Therapeutics, Inc. (AKBA)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Akebia Therapeutics, Inc. (AKBA)
Go deeper and ask any question about AKBA
Company Performance
Current Price
as of Sep 13, 2024$1.46
P/E Ratio
N/A
Market Cap
$307.02M
Description
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
Metrics
Overview
- HQCambridge, MA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerAKBA
- Price$1.46+1.39%
Trading Information
- Market Cap$307.02M
- Float94.97%
- Average Daily Volume (1m)1,646,028
- Average Daily Volume (3m)2,789,116
- EPS-$0.20
Company
- Revenue$174.50M
- Rev Growth (1yr)-22.58%
- Net Income-$8.58M
- Gross Margin60.03%
- EBITDA Margin1.57%
- EBITDA$0.68M
- EV$279.02M
- EV/Revenue1.60
- P/EN/A
- P/S1.75
Documents
SEC Filings
Factset Street Account